Premium
Chronic hepatitis B and non‐alcoholic fatty liver disease: Conspirators or competitors?
Author(s) -
Zhang Jianbin,
Lin Shuangzhe,
Jiang Daixi,
Li Mengting,
Chen Yuanwen,
Li Jun,
Fan Jiangao
Publication year - 2020
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.14369
Subject(s) - fatty liver , hepatocellular carcinoma , cirrhosis , medicine , disease , chronic hepatitis , chronic liver disease , alcoholic liver disease , immunology , gastroenterology , virus
Abstract Despite the widespread use of vaccines and antiviral drugs, approximately 350‐400 million patients with chronic hepatitis B (CHB) remain worldwide, who carry high risk of cirrhosis and liver carcinoma. Moreover, owing to improvements in global living standards and lifestyle changes, non‐alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease. Coexistence of NAFLD and CHB is commonly observed, especially in Asian CHB populations; however, little is known regarding the relationship between these two diseases as comorbidities. In this review, we summarize recent advances in clinical and basic researches related to the underlying mutual interactions, as well as potential animal models to facilitate further investigation.